FDA’s Tough Stance On Patient-Reported Outcomes Underscored At Repros Meeting
Executive Summary
US FDA advisory committee's insistence on symptom benefit as an efficacy endpoint for obesity-related secondary hypogonadism highlights importance of Repros' current efforts to lay groundwork for a patient-reported outcomes instrument for further study of enclomiphene.
You may also be interested in...
Real World Evidence: ‘Hot Topic’ At US FDA, But Not On Front Burner
Officials are enthusiastic about the possibility of ‘real world evidence’ supporting the regulatory process – but are also eager to tamp down expectations (or fears) that it will make a big difference any time soon.
Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures
US advisory committee rejects Repros Therapeutics' proposal for an obesity-related hypogonadism study in which efficacy is based upon testosterone levels and sperm concentrations.
Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene
Complete response letter from FDA follows abrupt cancellation of advisory committee meeting.